We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global POC Infectious Disease Market to Reach USD 1.9 Billion by 2025

By LabMedica International staff writers
Posted on 09 Jan 2018
The global point-of-care (POC) infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025, as the emerging trend of patient-centric services and increase in complicated infectious disorders drives an upsurge in the demand for portable and accurate detection devices.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Portable devices with the potential to enable rapid detection of infectious diseases are revolutionizing patient care and driving the growing demand for decentralized testing settings. More...
Additionally, increased R&D investments for the development of new products are expected to further drive the POC infectious disease diagnostics/testing market. For instance, an EU project research team has developed a new lab-on-a-disc' technology that aids in the diagnosis of various infectious diseases, including malaria. Through POC treatment, the technology enables faster diagnosis and allows precise administration of drugs, thereby driving its adoption.

HIV POC is estimated to account for the largest share of the POC infectious disease diagnostics/testing market due to the rising incidence rate of the disease. Companies are also adopting a quality management approach towards the introduction of novel tests for HIV diagnosis. TB and drug resistant TB are anticipated to witness lucrative demand over the coming years on account of their rising incidence rate, fueled further by the implementation of fully or partially integrated nano/microscale technologies for developing drug resistant TB diagnostic devices.

The demand for the development of inexpensive, rapid, simple, and accurate tests capable of simultaneously detecting multiple biomarkers is expected to contribute to the market growth. Moreover, advances in bio sensing technology for early detection with sensitivity are expected to drive revenue for the market players over the coming years.

Geographically, North America dominates the global market for POC infectious disease diagnostics/testing, due to adequate administration support, well-established healthcare framework, and extensive R&D upgradation in the region. However, the Asia Pacific market is expected to record the fastest growth over the forecast period due to the rising incidence and prevalence rates of infectious diseases in the region as well as favorable government support.

Related Links:
Research and Markets


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.